Facebook picto   picto linkdink   picto tiwter

News & Media

Jul 24, 2018
Less-invasive prostate cancer treatment receives FDA clearance

EDAP-TMS

Less-invasive prostate cancer treatment receives FDA clearance

521tech - Posted July 3rd, 2018 - By Nicole Cobler

Prostate cancer patients around the country will soon have a less-invasive, radiation-free treatment option. French company EDAP TMS, which made Austin its U.S. headquarters two years ago, has received U.S. Food and Drug Administration clearance for “Focal One” — a treatment for prostate cancer using high-intensity focused ultrasound. 

Learn more